Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)

Neuropharmacology

Volumn 99, Issue , 2015, Pages 546-553

  Rickli, Anna ^a   Luethi, Dino ^a   Reinisch, Julian ^a   Buchy, Danièle ^b   Hoener, Marius C ^b   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Affinity; Hallucinogens; Novel psychoactive substances; Phenethylamines; Receptor

Indexed keywords

2,5 DIMETHOXY PHENETHYLAMINE DERIVATIVE; ALPHA 1A ADRENERGIC RECEPTOR; CELL RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; HISTAMINE H1 RECEPTOR; LYSERGIDE; MESCALINE; N 2 METHOXYBENZYL PHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; PSYCHOTROPIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG; NEUROTRANSMITTER UPTAKE INHIBITOR; PROTEIN BINDING; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SUBSTITUTION; EC50; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; 3T3 CELL LINE; ANIMAL; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; MOUSE; PRECLINICAL STUDY; RADIOASSAY;

ANIMALS; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; MICE; MOLECULAR STRUCTURE; NEUROTRANSMITTER UPTAKE INHIBITORS; NIH 3T3 CELLS; PHENETHYLAMINES; PROTEIN BINDING; PSYCHOTROPIC DRUGS; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SEROTONIN, 5-HT2;

EID: 84940535904     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.08.034     Document Type: Article

References (58)

1. C. Acuna-Castillo, C. Villalobos, P.R. Moya, P. Saez, B.K. Cassels, and J.P. Huidobro-Toro Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors Br. J. Pharmacol. 136 2002 510 519
2. P. Armenian, and R.R. Gerona The electric Kool-Aid NBOMe test: LC-TOF/MS confirmed 2C-C-NBOMe (25C) intoxication at Burning Man Am. J. Emerg. Med. 32 2014 1444.e3 1444.e5
3. F.S. Bersani, O. Corazza, G. Albano, G. Valeriani, R. Santacroce, F. Bolzan Mariotti Posocco, E. Cinosi, P. Simonato, G. Martinotti, G. Bersani, and F. Schifano 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug Biomed. Res. Int. 2014 2014 734749
4. S. Bhattacharyya, A.H. Schapira, D.P. Mikhailidis, and J. Davar Drug-induced fibrotic valvular heart disease Lancet 374 2009 577 585
5. A.R. Blaazer, P. Smid, and C.G. Kruse Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT2A receptors ChemMedChem 3 2008 1299 1309
6. M.R. Braden, J.C. Parrish, J.C. Naylor, and D.E. Nichols Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists Mol. Pharmacol. 70 2006 1956 1964
7. S.P. Crouch, R. Kozlowski, K.J. Slater, and J. Fletcher The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity J. Immunol. Methods 160 1993 81 88
8. B.V. Dean, S.J. Stellpflug, A.M. Burnett, and K.M. Engebretsen 2C or not 2C: phenethylamine designer drug review J. Med. Toxicol. 9 2013 172 178
9. B. Di Cara, R. Maggio, G. Aloisi, J.M. Rivet, E.G. Lundius, T. Yoshitake, P. Svenningsson, M. Brocco, A. Gobert, L. De Groote, L. Cistarelli, S. Veiga, C. De Montrion, M. Rodriguez, J.P. Galizzi, B.P. Lockhart, F. Coge, J.A. Boutin, P. Vayer, P.M. Verdouw, L. Groenink, and M.J. Millan Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA) J. Neurosci. 31 2011 16928 16940
10. A.J. Eshleman, M.J. Forster, K.M. Wolfrum, R.A. Johnson, A. Janowsky, and M.B. Gatch Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function Psychopharmacol. Berl. 231 2014 875 888
11. A. Ettrup, M. Hansen, M.A. Santini, J. Paine, N. Gillings, M. Palner, S. Lehel, M.M. Herth, J. Madsen, J. Kristensen, M. Begtrup, and G.M. Knudsen Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers Eur. J. Nucl. Med. Mol. Imaging 38 2011 681 693
12. A. Ettrup, M. Palner, N. Gillings, M.A. Santini, M. Hansen, B.R. Kornum, L.K. Rasmussen, K. Nagren, J. Madsen, M. Begtrup, and G.M. Knudsen Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET J. Nucl. Med. 51 2010 1763 1770
13. W.E. Fantegrossi, B.W. Gray, J.M. Bailey, D.A. Smith, M. Hansen, and J.L. Kristensen Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice Psychopharmacol. Berl. 232 2015 1039 1047
14. M.B. Forrester 2C series phenethylamine derivative exposures in Texas Subst. Abus. 34 2013 81 82
15. M.B. Forrester NBOMe designer drug exposures reported to Texas poison centers J. Addict. Dis. 33 2014 196 201
16. R.A. Glennon, R. Raghupathi, P. Bartyzel, M. Teitler, and S. Leonhardt Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity J. Med. Chem. 35 1992 734 740
17. A.L. Halberstadt Recent advances in the neuropsychopharmacology of serotonergic hallucinogens Behav. Brain Res. 277 2015 99 120
18. A.L. Halberstadt, and M.A. Geyer Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens Neuropharmacology 61 2011 364 381
19. A.L. Halberstadt, and M.A. Geyer Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement Psychopharmacol. Berl. 227 2013 727 739
20. A.L. Halberstadt, and M.A. Geyer Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response Neuropharmacology 77 2014 200 207
21. M. Hansen, K. Phonekeo, J.S. Paine, S. Leth-Petersen, M. Begtrup, H. Brauner-Osborne, and J.L. Kristensen Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists ACS Chem. Neurosci. 5 2014 243 249
22. R. Heim Synthesis and Pharmacology of Potent 5-HT2A Receptor Agonists Which Have a Partial N-2-2-methoxybenzyl Structure 2004 Department of Chemistry. Freie Universität Berlin Germany, Berlin
23. S.L. Hill, T. Doris, S. Gurung, S. Katebe, A. Lomas, M. Dunn, P. Blain, and S.H. Thomas Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series Clin. Toxicol. 51 2013 487 492
24. S.L. Hill, and S.H. Thomas Clinical toxicology of newer recreational drugs Clin. Toxicol. 49 2011 705 719
25. C.M. Hysek, L.D. Simmler, V. Nicola, N. Vischer, M. Donzelli, S. Krähenbühl, E. Grouzmann, M.C. Hoener, and M.E. Liechti Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study PLoS One 7 2012 e36476
26. S. Leth-Petersen, C. Bundgaard, M. Hansen, M.A. Carnerup, J. Kehler, and J.L. Kristensen Correlating the metabolic stability of psychedelic 5-HT2A agonists with anecdotal reports of human oral bioavailability Neurochem. Res. 39 2014 2018 2023
27. A.H. Lewin, H.A. Navarro, and S.W. Mascarella Structure-activity correlations for β-phenethylamines at human trace amine receptor 1 Bioorg. Med. Chem. 16 2008 7415 7423
28. M. Lobos, Y. Borges, E. Gonzalez, and B.K. Cassels The action of the psychoactive drug 2C-B on isolated rat thoracic aorta Gen. Pharmacol. 23 1992 1139 1142
29. F. Nagai, R. Nonaka, and K. Satoh Hisashi Kamimura The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain Eur. J. Pharmacol. 559 2007 132 137
30. D.L. Nelson, V.L. Lucaites, D.B. Wainscott, and R.A. Glennon Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors Naunyn Schmiedeb. Arch. Pharmacol. 359 1999 1 6
31. D.E. Nichols Hallucinogens Pharmacol. Ther. 101 2004 131 181
32. D.E. Nichols, S.P. Frescas, B.R. Chemel, K.S. Rehder, D. Zhong, and A.H. Lewin High specific activity tritium-labeled N-(2-2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand Bioorg. Med. Chem. 16 2008 6116 6123
33. D.E. Nichols, M.F. Sassano, A.L. Halberstadt, L.M. Klein, S.D. Brandt, S.P. Elliott, and W.J. Fiedler N-Benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues ACS Chem. Neurosci. 6 2015 1165 1175
34. A. Ninnemann, and G.L. Stuart The NBOMe series: a novel, dangerous group of hallucinogenic drugs J. Stud. Alcohol. Drugs 74 2013 977 978
35. T. Passie, J.H. Halpern, D.O. Stichtenoth, H.M. Emrich, and A. Hintzen The pharmacology of lysergic acid diethylamide: a review CNS Neurosci. Ther. 14 2008 295 314
36. J.L. Poklis, C.R. Nanco, M.M. Troendle, C.E. Wolf, and A. Poklis Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication Drug Test. Anal. 6 2014 764 769
37. F.G. Revel, J.L. Moreau, R.R. Gainetdinov, A. Bradaia, T.D. Sotnikova, R. Mory, S. Durkin, K.G. Zbinden, R. Norcross, C.A. Meyer, V. Metzler, S. Chaboz, L. Ozmen, G. Trube, B. Pouzet, B. Bettler, M.G. Caron, J.G. Wettstein, and M.C. Hoener TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity Proc. Natl. Acad. Sci. U. S. A. 108 2011 8485 8490
38. A. Rickli, M.C. Hoener, and M.E. Liechti Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones Eur. Neuropsychopharmacol. 25 2015 365 376
39. A. Rickli, S. Kopf, M.C. Hoener, and M.E. Liechti Pharmacological profile of novel psychoactive benzofurans Br. J. Pharmacol. 172 2015 3412 3425
40. S.R. Rose, J.L. Poklis, and A. Poklis A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug Clin. Toxicol. 51 2013 174 177
41. B.L. Roth, M.S. Choudhary, N. Khan, and A.Z. Uluer High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model J. Pharmacol. Exp. Ther. 280 1997 576 583
42. P. Saez, Y. Borges, E. Gonzalez, and B.K. Cassels α-Adrenergic and 5-HT2-serotonergic effects of some β-phenylethylamines on isolated rat thoracic aorta Gen. Pharmacol. 25 1994 211 216
43. V. Setola, S.J. Hufeisen, K.J. Grande-Allen, I. Vesely, R.A. Glennon, B. Blough, R.B. Rothman, and B.L. Roth 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro Mol. Pharmacol. 63 2003 1223 1229
44. A.T. Shulgin, and A. Shulgin PiHKAL - a Chemical Love Story 1991 Transform Press Berkeley
45. L.D. Simmler, T.A. Buser, M. Donzelli, Y. Schramm, L.H. Dieu, J. Huwyler, S. Chaboz, M.C. Hoener, and M.E. Liechti Pharmacological characterization of designer cathinones in vitro Br. J. Pharmacol. 168 2013 458 470
46. L.D. Simmler, A. Rickli, M.C. Hoener, and M.E. Liechti Monoamine transporter and receptor interaction profiles of a new series of designer cathinones Neuropharmacology 79 2014 152 160
47. L.D. Simmler, A. Rickli, Y. Schramm, M.C. Hoener, and M.E. Liechti Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives Biochem. Pharmacol. 88 2014 237 244
48. S. Srisuma, A.C. Bronstein, and C.O. Hoyte NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System Clin. Toxicol. 53 2015 624 628
49. S.J. Stellpflug, S.E. Kealey, C.B. Hegarty, and G.C. Janis 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing J. Med. Toxicol. 10 2014 45 50
50. R.J. Strassman Human psychopharmacology of N,N-dimethyltryptamine Behav. Brain Res. 73 1996 121 124
51. M. Tatsumi, K. Groshan, R.D. Blakely, and E. Richelson Pharmacological profile of antidepressants and related compounds at human monoamine transporters Eur. J. Pharmacol. 340 1997 249 258
52. M. Titeler, R.A. Lyon, and R.A. Glennon Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens Psychopharmacol. Berl. 94 1988 213 216
53. C.A. Villalobos, P. Bull, P. Saez, B.K. Cassels, and J.P. Huidobro-Toro 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes Br. J. Pharmacol. 141 2004 1167 1174
54. F.X. Vollenweider, M.F. Vollenweider-Scherpenhuyzen, A. Babler, H. Vogel, and D. Hell Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport 9 1998 3897 3902
55. J.P. Walterscheid, G.T. Phillips, A.E. Lopez, M.L. Gonsoulin, H.H. Chen, and L.A. Sanchez Pathological findings in 2 cases of fatal 25I-NBOMe toxicity Am. J. Forensic Med. Pathol. 35 2014 20 25
56. V.J. Watts, C.P. Lawler, D.R. Fox, K.A. Neve, D.E. Nichols, and R.B. Mailman LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors Psychopharmacol. Berl. 118 1995 401 409
57. D.M. Wood, R. Sedefov, A. Cunningham, and P.I. Dargan Prevalence of use and acute toxicity associated with the use of NBOMe drugs Clin. Toxicol. 53 2015 85 92
58. D.S.K. Zuba Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs Drug Test. Anal. 5 2012 634 645